Urothelial Carcinoma trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Urothelial Carcinoma. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month9 studies across 7 companies, in the next 180 days.
August 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| NRIX | Nurix Therapeutics, Inc. | A Study of NX-1607 in Adults With Advanced MalignanciesNCT05107674Incidence of treatment-emergent adverse events (TEAEs), including Grade ≥ 3 TEAEs, treatment-emergent serious adverse events (SAEs), TEAEs leading to study drug discontinuation, and deaths due to TEAEs | Phase 1 | Recruiting | 2026-08-31 | in 11 d | 2025-09-09 |
November 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| CGON | CG Oncology, Inc. | A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBTNCT06111235Recurrence Free Survival (RFS) | Phase 3 | Active, not recruiting | Nov 2026 | ≤ 102 d | 2026-07-01 |
| TYRA | Tyra Biosciences, Inc | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene AlterationsNCT05544552Phase 1 Part A: To determine the maximum tolerated doses (MTD). | Phase 1/2 | Active, not recruiting | Nov 2026 | ≤ 102 d | 2026-01-12 |
December 2026 4
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| PFE | Seagen, a wholly owned subsidiary of Pfizer | A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2NCT04879329Confirmed Objective Response Rate (cORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1) by blinded independent central review (BICR) (Cohorts A, B, C, and G) | Phase 2 | Recruiting | 2026-12-11 | in 113 d | 2026-07-22 |
| JAZZ | Jazz Pharmaceuticals | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsNCT06695845Confirmed Objective Response Rate (cORR) per RECIST Version 1.1, as assessed by ICR | Phase 2 | Recruiting | 2026-12-31 | in 133 d | 2026-07-10 |
| MNPR | Monopar Therapeutics | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid TumorsNCT06617169Identify the dose-limiting toxicities (DLTs) of fractionated MNPR-101-PCTA-177Lu dosing and their frequency | Phase 1 | Recruiting | Dec 2026 | ≤ 133 d | 2025-05-21 |
| PFE | Pfizer | Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are ClosingNCT05059522Number of participants with adverse events leading to permanent discontinuation of study intervention | Phase 3 | Active, not recruiting | 2026-12-31 | in 133 d | 2026-06-22 |
January 2027 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| PFE | Seagen, a wholly owned subsidiary of Pfizer | Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2NCT05911295Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by blinded independent central review (BICR) | Phase 3 | Active, not recruiting | 2027-01-29 | in 162 d | 2026-07-22 |
| EXEL | Exelixis | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsNCT05176483Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Including Immune-Mediated Adverse Events (imAEs) | Phase 1 | Recruiting | 2027-01-31 | in 164 d | 2026-08-05 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Urothelial Carcinoma
most recently updated first123 studies match. Showing the first 100 of 123 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CNTX | Context Therapeutics Inc. | $49M | A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial CancersNCT07545122Phase 1a: Incidence of Dose Limiting Toxicities (DLTs) | Phase 1 | Recruiting | Drug: CT-202 | Triple Negative Breast Cancer (TNBC), Colorectal Cancer, Urothelial Cancer | 162 | Sep 2026 | Jan 2030 | ≤ 1,260 d | 2026-08-18 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid TumorsNCT04895709Incidence of adverse events (AEs) | Phase 1/2 | Recruiting | Drug: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig | Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms | 1,109 | 2021-05-27 | 2031-08-31 | in 1,837 d | 2026-08-17 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary TractNCT07218380Number of participants with treatment-related adverse events related to vepugratinib in combination with EV and pembrolizumab | Phase 3 | Recruiting | Drug: Vepugratinib, EV, Pembrolizumab · Other: Placebo | Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis | 450 | 2025-12-12 | Oct 2029 | ≤ 1,168 d | 2026-08-17 |
| PFE | Pfizer | $155.3B | Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial CancerNCT07421700Confirmed Objective Response Rate (ORR) by investigator | Phase 1/2 | Recruiting | Biological: PF-08634404, Enfortumab Vedotin | Urothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial Carcinoma | 132 | 2026-03-11 | 2027-12-06 | in 473 d | 2026-08-17 |
| PFE | Pfizer | $155.3B | Tucatinib Continuation StudyNCT07768358To monitor the safety and tolerability of tucatinib | Phase 4 | Not yet recruiting | Drug: tucatinib | HER2-positive Breast Cancer, Cervical Cancer, Biliary Tract Neoplasms, Urothelial Cancer, Advanced Non-Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma (GEC), Colorectal Cancer | 175 | 2026-08-24 | 2032-03-13 | in 2,032 d | 2026-08-17 |
| AZN | AstraZeneca | — | Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)NCT05489211Objective response rate (ORR) | Phase 2 | Recruiting | Drug: Datopotamab deruxtecan (Dato-DXd), Capecitabine, 5-Fluorouracil, Volrustomig, Carboplatin, Bevacizumab, Rilvegostomig, Prednisone/ prednisolone, Cisplatin | Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer, Biliary Tract Cancer | 454 | 2022-09-06 | 2027-10-01 | in 407 d | 2026-08-13 |
| AURA | Aura Biosciences | $846M | A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder CancerNCT05483868Safety of AU-011: Incidences of SAEs and DLTs | Phase 1 | Active, not recruiting | Drug: AU-011 · Combination product: AU-011 in Combination with Medical Laser Adminstration, AU-011 in Combination with Medical Laser Administration | Non-muscle-invasive Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Carcinoma, Non-Muscle Invasive Bladder Neoplasms, Non-Muscle Invasive Bladder Urothelial Carcinoma, Urothelial Carcinoma Bladder | 55 | 2022-09-26 | Mar 2027 | ≤ 223 d | 2026-08-06 |
| STRO | Sutro Biopharma, Inc. | $365M | A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic CancerNCT07227168Part 1A: Number of participants with Dose-limiting Toxicities (DLTs) | Phase 1 | Recruiting | Drug: STRO-004, Pembrolizumab | Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Cervical Cancer, Endometrial Cancer, Urothelial Cancer | 200 | 2025-11-07 | Dec 2027 | ≤ 498 d | 2026-08-06 |
| EXEL | Exelixis | $13.2B | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsNCT05176483Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Including Immune-Mediated Adverse Events (imAEs) | Phase 1 | Recruiting | Drug: Zanzalintinib, Nivolumab, Ipilimumab, Nivolumab, Nivolumab, Nivolumab + Relatlimab, Prednisone, Docetaxel, DDI Probe Cocktail | Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor, Hepatocellular Carcinoma (HCC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma (HNSCC), Clear Cell Renal Cell Carcinoma (ccRCC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Drug-Drug Interaction (DDI) | 1,394 | 2021-12-14 | 2027-01-31 | in 164 d | 2026-08-05 |
| IDYA | IDEAYA Biosciences | $3.7B | A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid TumorsNCT07277413Incidence of Dose-limiting Toxicities (DLTs) of IDE892 (Parts 1 and 3) | Phase 1 | Recruiting | Drug: IDE892, IDE397 | NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus, Squamous Cell Car. - Esophagus, Urothelial Carcinoma (UC), Bladder Cancer, Mesothelioma, Pleural Mesothelioma, Peritoneal Mesothelioma, Non-Small Cell Lung Cancer NSCLC, Pancreatic Cancer, Biliary Tract Carcinoma | 260 | 2026-03-04 | 2028-04-30 | in 619 d | 2026-08-05 |
| INBX | Inhibrx Biosciences, Inc | $1.4B | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)NCT04198766Frequency of adverse events of INBRX-106 as single agent and in combination with pembrolizumab | Phase 1/2 | Recruiting | Drug: INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2, Gemcitabine (1000 mg/m2) | Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma, Resectable Non-Small-Cell Lung Cancer | 340 | 2019-12-10 | Jul 2033 | ≤ 2,537 d | 2026-07-29 |
| BMY | Bristol-Myers Squibb | $134.9B | Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After ImmunotherapyNCT07106762Phase 2: Recommended Phase 3 Dose (RP3D) of BMS-986507 | Phase 2/3 | Recruiting | Drug: Iza-bren, Cisplatin, Gemcitabine, Carboplatin | Urothelial Cancer | 470 | 2025-09-30 | 2029-01-26 | in 890 d | 2026-07-29 |
| 4568.T | Daiichi Sankyo | $31.7B | Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial CarcinomaNCT07129993Overall Response Rate - Part A (Phase 2) | Phase 2/3 | Recruiting | Drug: Dato-DXd, Carboplatin, Cisplatin, Gemcitabine | Urothelial Cancer, Bladder Cancer | 630 | 2025-09-26 | 2029-06-01 | in 1,016 d | 2026-07-27 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2NCT04879329Confirmed Objective Response Rate (cORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1) by blinded independent central review (BICR) (Cohorts A, B, C, and G) | Phase 2 | Recruiting | Drug: disitamab vedotin, pembrolizumab | Urothelial Carcinoma | 372 | 2022-05-03 | 2026-12-11 | in 113 d | 2026-07-22 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2NCT05911295Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by blinded independent central review (BICR) | Phase 3 | Active, not recruiting | Drug: disitamab vedotin, pembrolizumab, gemcitabine, cisplatin, carboplatin | Urothelial Carcinoma | 412 | 2023-09-22 | 2027-01-29 | in 162 d | 2026-07-22 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid TumorsNCT07090499Incidence of Treatment Emergent Adverse Events (TEAEs) estimated during the Adverse Events (AE) evaluation | Phase 1 | Recruiting | Drug: PF-08046876 | Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma, Non Small Cell Lung, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Cancer | 310 | 2025-08-20 | 2028-07-08 | in 688 d | 2026-07-22 |
| NTHI | Neonc Technologies, Inc. | $143M | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisNCT06047379Phase 1: safety and tolerability of increasing dose levels of orally administered NEO212 alone in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or patients with select solid tumors with uncontrolled metastases to the brain | Phase 1/2 | Recruiting | Drug: NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib, Carboplatin, Paclitaxel, FOLFIRI Protocol, Bevacizumab | Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma | 134 | 2023-11-01 | 2027-02-28 | in 192 d | 2026-07-16 |
| AZN | AstraZeneca | — | Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial CancerNCT02516241results2021-05-13To Assess the Efficacy of Durvalumab + Tremelimumab Combination Therapy Versus SoC in Terms of OS in Full Analysis Set | Phase 3 | Active, not recruiting | Drug: MEDI4736 (Durvalumab), Tremelimumab, Cisplatin, Carboplatin, Gemcitabine | Urothelial Cancer | 1,126 | 2015-11-02 | 2020-01-27actual | — | 2026-07-14 |
| GILD | Gilead Sciences | $177.9B | Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid TumorsNCT05101096Phase 1: Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) Defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 | Phase 1/2 | Active, not recruiting | Drug: Sacituzumab Govitecan-hziy | Advanced Solid Tumor, Metastatic Triple-Negative Breast Cancer, HR+/HER2- Metastatic Breast Cancer, Metastatic Urothelial Cancer | 135 | 2021-10-20 | May 2027 | ≤ 284 d | 2026-07-10 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsNCT06695845Confirmed Objective Response Rate (cORR) per RECIST Version 1.1, as assessed by ICR | Phase 2 | Recruiting | Drug: Zanidatamab | Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Urothelial Carcinoma, Salivary Gland Cancer, Pancreatic Cancer, HER-2 Protein Overexpression | 200 | 2025-01-14 | 2026-12-31 | in 133 d | 2026-07-10 |
| AKTS | Aktis Oncology, Inc. | — | A Study of [225Ac]Ac-AKY-1189 in Patients With Solid TumorsNCT07020117Part 1: Number of Patients with Dose-Limiting Toxicities | Phase 1 | Recruiting | Drug: [225Ac]Ac-AKY-1189 (therapeutic), [64Cu]Cu-AKY-1189 (imaging) | Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC), Hormone Receptor Positive Breast Adenocarcinoma, Non Small Cell Lung Cancer, Cervical Adenocarcinoma, Colorectal Adenocarcinoma, Head and Neck Cancer | 150 | 2025-08-22 | Dec 2027 | ≤ 498 d | 2026-07-10 |
| CGON | CG Oncology, Inc. | $6.8B | A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBTNCT06111235Recurrence Free Survival (RFS) | Phase 3 | Active, not recruiting | Drug: Cretostimogene Grenadenorepvec · Other: n-dodecyl-B-D-maltoside | Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma | 367 | 2023-12-14 | Nov 2026 | ≤ 102 d | 2026-07-01 |
| LLY | Eli Lilly and Company | $1.15T | Expanded Access for Vepugratinib (LY3866288) in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid TumorsNCT07675057expanded access | — | Available | Drug: Vepugratinib | Urinary Bladder Neoplasms, Neoplasm Metastasis, Carcinoma, Transitional Cell | — | — | — | — | 2026-06-30 |
| TARA | Protara Therapeutics | — | Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder CancerNCT07480356Incidence of high-grade complete response | Phase 3 | Recruiting | Drug: TARA-002, Investigator's Choice of Intravesical Chemotherapy | Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ | 284 | 2026-05-29 | Apr 2028 | ≤ 619 d | 2026-06-29 |
| PFE | Pfizer | $155.3B | Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are ClosingNCT05059522Number of participants with adverse events leading to permanent discontinuation of study intervention | Phase 3 | Active, not recruiting | Drug: Avelumab, Lorlatanib, Talazoparib, Pemetrexed, Axitinib, CMP 001, Utomilumab, PF04518600 | Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer, Solid Tumors | 77 | 2021-09-29 | 2026-12-31 | in 133 d | 2026-06-22 |
| GENB | Generate Biomedicines | $2.0B | Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial CancerNCT07484022Incidence of AEs and SAEs | Phase 1 | Recruiting | Drug: GB-4362, enfortumab vedotin (EV), Pembrolizumab | Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma | 37 | Jun 2026 | Jun 2027 | ≤ 314 d | 2026-06-18 |
| URGN | UroGen Pharma Ltd. | $2.4B | A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial CancerNCT06774131Complete response rate (CRR) | Phase 3 | Recruiting | Drug: UGN-104 | Upper Urinary Tract Urothelial Carcinoma, Urothelial Carcinoma | 70 | 2025-08-06 | Mar 2027 | ≤ 223 d | 2026-06-16 |
| AZN | AstraZeneca | — | Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial CancerNCT03682068Overall Survival (OS) | Phase 3 | Active, not recruiting | Drug: Durvalumab, Tremelimumab, Cisplatin + Gemcitabine, Carboplatin + Gemcitabine | Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer | 1,246 | 2018-09-27 | 2026-06-01 | — | 2026-05-28 |
| PFE | Pfizer | $155.3B | A Real-world Study of the First Treatment and Outcomes of Patients With Advanced or Metastatic Bladder CancerNCT07386847observationalReal world Progression Free Survival (rwPFS) | — | Completed | — | Metastatic Urothelial Carcinoma, Urothelial Cancer, Urothelial Carcinoma, Locally Advanced or Metastatic Urothelial Carcinoma | 1 | 2026-02-12 | 2026-03-30actual | — | 2026-05-28 |
| URGN | UroGen Pharma Ltd. | $2.4B | A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerNCT05243550results2024-11-04Complete Response Rate (CRR) | Phase 3 | Active, not recruiting | Drug: UGN-102 | Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder | 240 | 2022-03-01 | 2023-04-26actual | — | 2026-05-11 |
| INCY | Incyte Corporation | $24.7B | A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial CarcinomaNCT02298153Incidence of adverse events (AEs) | Phase 1 | Terminatedsponsor's stated reason: Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention. | Drug: Epacadostat, Atezolizumab | NSCLC (Non-small Cell Lung Carcinoma), UC (Urothelial Cancer) | 29 | 2015-01-27 | 2017-11-08actual | — | 2026-04-20 |
| CGON | CG Oncology, Inc. | $6.8B | An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCGNCT06443944expanded access | — | Available | Drug: Cretostimogene Grenadenorepvec · Other: n-dodecyl-B-D-maltoside | Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma, Urologic Cancer, Bladder Cancer | — | — | — | — | 2026-04-14 |
| PFE | Pfizer | $155.3B | A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMANCT04822350results2026-04-02observationalOverall Survival (OS): Overall | — | Completed | Drug: Avelumab | Urothelial Carcinoma | 596 | 2021-07-13 | 2024-04-25actual | — | 2026-04-02 |
| RLMD | Relmada Therapeutics, Inc. | $517M | A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBTNCT07313891To compare DFS between study arms | Phase 3 | Withdrawnsponsor's stated reason: This study has been incorporated into the Relmada REL-NDV01-303 study. | Drug: NDV-01 (sustained-release gemcitabine-docetaxel) | Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Bladder (Urothelial, Transitional Cell) Cancer, Urothelial Carcinoma Bladder, Urologic Cancer | 0 | 2026-05-01 | 2029-09-01 | in 1,108 d | 2026-03-17 |
| RLMD | Relmada Therapeutics, Inc. | $517M | A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line TherapyNCT07342517To evaluate the efficacy of NDV-01 (determined by complete response [CR] anytime) administered by intravesical instillation in patients with BCG-unresponsive NMIBC who have recurred after first-line intravesical therapy (approved or in development). | Phase 3 | Withdrawnsponsor's stated reason: This study has been incorporated into the Relmada REL-NDV01-303 study. | Drug: NDV-01 (sustained-release gemcitabine-docetaxel) | Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent, Urologic Cancer | 0 | 2026-06-30 | 2027-06-30 | in 314 d | 2026-03-17 |
| GILD | Gilead Sciences | $177.9B | Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has SpreadNCT03547973Overall Response Rate (ORR) Based on Central Review by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Criteria (Cohorts 1 to 4 and 6) | Phase 2 | Recruiting | Drug: Sacituzumab Govitecan-hziy, Pembrolizumab, Cisplatin, Avelumab, Zimberelimab, Carboplatin, Gemcitabine, Domvanalimab, Enfortumab Vedotin | Metastatic Urothelial Cancer | 827 | 2018-08-13 | Apr 2030 | ≤ 1,349 d | 2026-03-16 |
| RLMD | Relmada Therapeutics, Inc. | $517M | A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder CancerNCT07464145Disease Free Survival in participants with Intermediate Risk NMIBC | Phase 3 | Not yet recruiting | Drug: NDV-01 (sustained-release gemcitabine-docetaxel) | Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent, Urologic Cancer | 393 | Jun 2026 | Sep 2029 | ≤ 1,137 d | 2026-03-11 |
| BMY | Bristol-Myers Squibb | $134.9B | Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial CancerNCT03036098results2025-09-18Overall Survival (OS) in Cisplatin-ineligible Randomized Participants for Primary Study | Phase 3 | Active, not recruiting | Biological: Nivolumab, Ipilimumab · Drug: Gemcitabine, Cisplatin, Carboplatin | Urothelial Cancer | 1,314 | 2017-03-24 | 2024-08-30actual | — | 2026-03-06 |
| PFE | Pfizer | $155.3B | PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid TumorsNCT05233436Number of participants with Dose-limiting toxicities (DLTs) in Dose Escalation (Part 1) | Phase 1 | Terminatedsponsor's stated reason: Study terminated based on internal business considerations and was not based on safety reasons | Drug: PF-07265028 · Biological: Sasanlimab | Advanced Solid Tumors, Gastric Cancer, Gastroesophageal Junction Cancer, Urothelial Cancer, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinomas | 21 | 2022-02-24 | 2023-10-16actual | — | 2026-02-19 |
| URGN | UroGen Pharma Ltd. | $2.4B | A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder CancerNCT06331299Complete response rate (CRR) | Phase 3 | Active, not recruiting | Drug: UGN-103 | Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder | 99 | 2024-08-29 | 2025-09-11actual | — | 2026-01-15 |
| IBRX | ImmunityBio, Inc. | $8.2B | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsNCT03228667ORR, defined as Investigator-assessed CR + PR per RECIST v1.1. | Phase 2 | Active, not recruiting | Drug: N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab, N-803 + Avelumab, N-803 + Durvalumab, N-803 + Pembrolizumab + PD-L1 t-haNK, N-803 + Nivolumab + PD-L1 t-haNK, N-803 + Atezolizumab + PD-L1 t-haNK, N-803 + Avelumab + PD-L1 t-haNK, N-803 + Durvalumab + PD-L1 t-haNK, N-803 + Docetaxel + Pembrolizumab, N-803 + Docetaxel + Nivolumab | Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Colorectal Cancer | 40 | 2018-12-11 | 2029-08-31 | in 1,107 d | 2026-01-14 |
| URGN | UroGen Pharma Ltd. | $2.4B | A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)NCT05375903Incidence of dose-limiting toxicities (DLTs) and treatment-emergent adverse events (TEAEs) | Phase 1 | Completed | Drug: UGN-301, UGN-201, Gemcitabine | Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent | 51 | 2022-06-01 | 2026-01-09actual | — | 2026-01-14 |
| INDP | Indaptus Therapeutics, Inc | $125M | Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid TumorsNCT05651022Number of Subjects with dose-limiting toxicities (DLTs) | Phase 1/2 | Active, not recruiting | Drug: Decoy20, Tislelizumab | Solid Tumor, Adult, HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer), Pancreatic Adenocarcinoma, NSCLC Non-small Cell Lung Cancer, Squamous Cell Cancer of the Head and Neck, UC (Urothelial Cancer), MSI-H Cancer | 120 | 2023-02-28 | 2027-06-30 | in 314 d | 2026-01-13 |
| TYRA | Tyra Biosciences, Inc | $1.6B | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene AlterationsNCT05544552Phase 1 Part A: To determine the maximum tolerated doses (MTD). | Phase 1/2 | Active, not recruiting | Drug: TYRA-300 | Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor, Urothelial Carcinoma, Solid Tumor, Adult, Bladder Cancer, Non-muscle-invasive Bladder Cancer, FGFR3 Gene Mutation, FGFR3 Gene Alteration, Advanced Solid Tumor, Advanced Urothelial Carcinoma, Urinary Tract Cancer, Urinary Tract Tumor, Urinary Tract Carcinoma | 310 | 2022-11-22 | Nov 2026 | ≤ 102 d | 2026-01-12 |
| 051910.KS | LG Chem | $13.7B | Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLCNCT06332755Phase 1a: MTD and/or RP2D of LB-LR1109 as monotherapy in participants with advanced or metastatic solid tumors / Phase 1b: MTD and/or RP2D of LB-LR1109 as combination therapy with atezolizumab in participants with advanced or metastatic NSCLC | Phase 1 | Recruiting | Drug: Phase 1a: LB-LR1109, Phase 1b: LB-LR1109 and Atezolizumab | Non-small Cell Lung Cancer(NSCLC), Head and Neck Squamous Cell Carcinoma(HNSCC), Renal Cell Carcinoma(RCC), Urothelial Carcinoma, Malignant Melanoma | 76 | 2024-06-05 | Nov 2027 | ≤ 467 d | 2025-11-24 |
| INCY | Incyte Corporation | $24.7B | Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)NCT04003610results2022-05-25Progression-free Survival (PFS) | Phase 2 | Terminatedsponsor's stated reason: The reason this study was terminated was due to a business decision. There were no safety concerns that contributed to this decision. | Drug: Pemigatinib, Pembrolizumab, Gemcitabine, Carboplatin | Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma | 7 | 2020-05-14 | 2021-04-18actual | — | 2025-11-04 |
| INCY | Incyte Corporation | $24.7B | An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial CarcinomaNCT04586244results2025-03-10Change From Baseline in CD8+ Lymphocytes Within the Resected Tumor | Phase 2 | Terminatedsponsor's stated reason: Business Decision. No safety concerns contributed to this decision. | Drug: retifanlimab, epacadostat, INCAGN02385, INCAGN02390 | Urothelial Carcinoma | 30 | 2022-01-14 | 2024-01-29actual | — | 2025-10-30 |
| PFE | Pfizer | $155.3B | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid TumorsNCT06285097Number of patients with dose limiting toxicities (DLTs) in dose escalation (Part 1A and Part 1B) | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns. | Drug: PF-07820435 · Biological: Sasanlimab | Neoplasms, Non-small-cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Urothelial Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma | 9 | 2024-02-08 | 2025-01-03actual | — | 2025-09-17 |
| TPST | Tempest Therapeutics | $16M | Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid TumorsNCT04344795Determination of maximum tolerated dose and/or recommended Phase 2 dose (RP2D) and optimum dose schedule for TPST-1495 as a single agent and in combination with pembrolizumab | Phase 1 | Completed | Drug: TPST-1495 twice daily, TPST-1495 once daily or on intermittent schedule, Pembrolizumab | Solid Tumor, Colorectal Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Endometrial Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma, Solid Tumors With PIK3Ca Mutation | 89 | 2020-05-06 | 2024-09-25actual | — | 2025-09-12 |
| NRIX | Nurix Therapeutics, Inc. | $2.8B | A Study of NX-1607 in Adults With Advanced MalignanciesNCT05107674Incidence of treatment-emergent adverse events (TEAEs), including Grade ≥ 3 TEAEs, treatment-emergent serious adverse events (SAEs), TEAEs leading to study drug discontinuation, and deaths due to TEAEs | Phase 1 | Recruiting | Drug: NX-1607, Paclitaxel | Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic or Unresectable Melanoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM), Triple Negative Breast Cancer (TNBC), Metastatic Urothelial Carcinoma, Cervical Cancer, Diffuse Large B Cell Lymphoma (DLBCL), Richter Transformation, Microsatellite Stable Colorectal Carcinoma | 345 | 2021-09-29 | 2026-08-31 | in 11 d | 2025-09-09 |
| INCY | Incyte Corporation | $24.7B | Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)NCT03361865results2019-08-29Objective Response Rate (ORR) With Pembrolizumab + Epacadostat Versus Pembrolizumab + Placebo | Phase 3 | Completed | Drug: Pembrolizumab, Epacadostat, Placebo | UC (Urothelial Cancer) | 93 | 2017-12-04 | 2018-08-09actual | — | 2025-08-22 |
| INCY | Incyte Corporation | $24.7B | Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial CarcinomaNCT03374488results2019-08-28Objective Response Rate (ORR) With Pembrolizumab + Epacadostat Versus Pembrolizumab + Placebo | Phase 3 | Completed | Drug: Pembrolizumab, Epacadostat, Placebo | UC (Urothelial Cancer) | 84 | 2017-12-22 | 2018-07-27actual | — | 2025-08-22 |
| EXEL | Exelixis | $13.2B | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsNCT03170960Dose Escalation: MTD/Recommended Dose | Phase 1 | Active, not recruiting | Drug: cabozantinib, atezolizumab, cabozantinib, cabozantinib | Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer, Head and Neck Cancer, Differentiated Thyroid Cancer, Lower Esophageal Cancer | 914 | 2017-09-05 | 2023-02-21actual | — | 2025-08-17 |
| INCY | Incyte Corporation | $24.7B | A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)NCT02872714results2023-03-24Objective Response Rate (ORR) in Participants With FGFR3 Mutations or Fusions on a CD Regimen | Phase 2 | Completed | Drug: pemigatinib, pemigatinib | UC (Urothelial Cancer) | 263 | 2017-01-12 | 2022-02-01actual | — | 2025-08-14 |
| MGNX | MacroGenics | $261M | Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory CancerNCT02475213results2025-08-11Number of Participants With Dose-limiting Toxicities (DLT) After Administration of Enoblituzumab and Pembrolizumab or Retifanlimab | Phase 1 | Completed | Biological: Enoblituzumab Schedule 1, Pembrolizumab, Enoblituzumab Schedule 2, retifanlimab | Melanoma, Head and Neck Cancer, Non Small Cell Lung Cancer, Urothelial Carcinoma | 146 | Jul 2015 | 2021-08-18actual | — | 2025-08-11 |
| ABBV | AbbVie | $457.5B | Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)NCT06632951Overall Survival (OS) | Phase 2 | Active, not recruiting | Drug: Livmoniplimab, Budigalimab, Docetaxel, Paclitaxel, Docetaxel, Paclitaxel, Gemcitabine | Urothelial Carcinoma | 150 | 2025-01-20 | Mar 2027 | ≤ 223 d | 2025-08-11 |
| XNCR | Xencor, Inc. | $1.9B | Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid TumorsNCT05585034Incidence of treatment-emergent adverse events (TEAEs) | Phase 1 | Completed | Biological: XmAb®808, Keytruda® (pembrolizumab) | Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous, Urothelial Carcinoma, Renal Cell Carcinoma, Clear Cell, Castration-resistant Prostate Cancer, Ovarian Cancer, Epithelial, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer | 60 | 2022-12-14 | 2025-05-20actual | — | 2025-08-07 |
| INCY | Incyte Corporation | $24.7B | Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid TumorsNCT02903914results2021-09-30Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Phase 1 | Completed | Drug: INCB001158, Pembrolizumab | Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer, Head and Neck Cancer, Lung Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, UC (Urothelial Cancer), Mesothelioma | 260 | 2016-09-14 | 2020-04-30actual | — | 2025-08-05 |
| ALXO | ALX Oncology Inc. | $288M | A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)NCT05524545First Cycle Dose limiting toxicities (DLTs) | Phase 1 | Completed | Drug: Evorpacept, Enfortumab Vedotin | Bladder Cancer, Urothelial Carcinoma | 36 | 2022-11-02 | 2025-06-27actual | — | 2025-07-25 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | HER2 and LA/mUC: A Multi-country Chart Review Cohort StudyNCT05902494observationalReal-world Objective Response Rate (rwORR) per modified response evaluation criteria in solid tumors version 1.1 (RECIST v1.1) | — | Completed | — | Urothelial Carcinoma | 389 | 2023-06-29 | 2025-06-18actual | — | 2025-07-20 |
| INCY | Incyte Corporation | $24.7B | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid TumorsNCT04242199Number of treatment-emergent adverse events | Phase 1 | Completed | Drug: INCB099280 | Advanced Solid Tumor, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer, HepatoCellular Carcinoma, Esophageal Squamous Cell Carcinoma, Merkel Cell Carcinoma, Small-cell Lung Cancer, Mesothelioma, PD-L1 Amplified Tumor (9p24.1), Nasopharyngeal Carcinoma | 182 | 2020-09-04 | 2024-08-29actual | — | 2025-07-14 |
| INO | Inovio Pharmaceuticals | $124M | INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial CarcinomaNCT03502785Number of Adverse Events | Phase 1/2 | Completed | Biological: INO-5401, INO-9012 · Drug: Atezolizumab · Device: CELLECTRA™ 2000 | Urothelial Carcinoma | 35 | 2018-05-24 | 2025-05-09actual | — | 2025-07-10 |
| EXEL | Exelixis | $13.2B | A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid TumorsNCT06630247Dose-escalation and Dose-finding Stages: Number of Participants with Treatment-Emergent Adverse Events | Phase 1 | Terminatedsponsor's stated reason: Company Decision | Drug: XL495, ADC cytotoxic agents | Solid Cancers, Solid Tumor Cancer, Solid Tumor Malignancy, Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer), Metastatic Solid Tumor, Locally Advanced Solid Tumor, Urothelial Cancer of Renal Pelvis | 9 | 2024-10-17 | 2025-05-07actual | — | 2025-06-25 |
| CLDX | Celldex Therapeutics | $3.3B | A Study of CDX-585 in Patients With Advanced MalignanciesNCT05788484Dose escalation: To determine the maximum tolerated dose of CDX-585 and to select the CDX-585 dose(s) for evaluation in tumor-specific expansion cohorts | Phase 1 | Completed | Drug: CDX-585 | Non-small Cell Lung Cancer, Gastric Cancer, Head and Neck Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Bladder Urothelial Carcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Renal Cell Carcinoma, Cholangiocarcinoma, Pancreatic Cancer, Other Solid Tumors | 20 | 2023-05-11 | 2025-05-21actual | — | 2025-06-15 |
| BMY | Bristol-Myers Squibb | $134.9B | Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in FranceNCT06421311observationalDisease-free survival (DFS) of participants | — | Terminatedsponsor's stated reason: Business objectives have changed | Drug: nivolumab | Urothelial Carcinoma | 176 | 2024-07-30 | 2025-04-04actual | — | 2025-06-05 |
| PFE | Pfizer | $155.3B | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.NCT04152018Number of participants with Dose-limiting toxicities (DLT) for Dose Escalation and Dose Finding | Phase 1 | Terminatedsponsor's stated reason: Study termination was based on strategic considerations and not due to specific safety reasons or a request from a regulatory authority. | Drug: PF-06940434, PF-06801591 | Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Lung Squamous Cell Carcinoma, Pancreatic Cancer, Bile Duct Cancer, Endometrial Cancer, Melanoma Cancer, Urothelial Cancer | 85 | 2019-11-13 | 2024-12-10actual | — | 2025-05-28 |
| MNPR | Monopar Therapeutics | $799M | Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid TumorsNCT06337084To assess dosimetry and biodistribution of MNPR-101-DFO*-89Zr | Phase 1 | Recruiting | Drug: MNPR-101-DFO*-89Zr · Diagnostic test: PET/CT Diagnostic Imaging | Solid Tumor, Adult, Bladder Cancer, Urothelial Carcinoma, Triple-negative Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Ovarian Cancer, Pancreatic Cancer | 12 | 2024-05-30 | Apr 2026 | — | 2025-05-22 |
| MNPR | Monopar Therapeutics | $799M | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid TumorsNCT06617169Identify the dose-limiting toxicities (DLTs) of fractionated MNPR-101-PCTA-177Lu dosing and their frequency | Phase 1 | Recruiting | Drug: MNPR-101-PCTA-177Lu | Solid Tumor, Adult, Bladder Cancer, Urothelial Carcinoma, Triple-negative Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Ovarian Cancer, Pancreatic Cancer | 12 | 2024-10-08 | Dec 2026 | ≤ 133 d | 2025-05-21 |
| APRE | Aprea Therapeutics | $8M | Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor MalignanciesNCT04383938results2025-05-13To Evaluate the Safety of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumors. | Phase 1/2 | Completed | Drug: APR-246 (eprenetapopt) + Pembrolizumab | Bladder Cancer, Gastric Cancer, Non Small Cell Lung Cancer, NSCLC, Urothelial Carcinoma, Advanced Solid Tumor | 40 | 2020-06-25 | 2022-04-30actual | — | 2025-05-13 |
| AZN | AstraZeneca | — | Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDERNCT05945108observationalClinical staging | — | Completed | — | Urothelial Carcinoma, Non Muscle Invasive Bladder Cancer, Muscle-invasive Bladder Cancer | 400 | 2023-07-10 | 2024-04-18actual | — | 2025-04-11 |
| STTK | Shattuck Labs, Inc. | $748M | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or LymphomasNCT03894618results2025-03-14Safety Profile of SL-279252 | Phase 1 | Completed | Drug: SL-279252 | Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Squamous Cell Carcinoma of the Anus, Squamous Cell Carcinoma of the Cervix, Squamous Cell Carcinoma of the Skin, Renal Cell Carcinoma, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Mismatch Repair Deficient or MSI-High Solid Tumors | 49 | 2019-03-26 | 2023-05-04actual | — | 2025-04-02 |
| INCY | Incyte Corporation | $24.7B | Study of INCB086550 in Select Solid TumorsNCT04629339results2025-03-13Objective Response Rate (ORR) | Phase 2 | Terminatedsponsor's stated reason: Strategic business decision to terminate the study effective immediately. This is due to a company decision to prioritize another oral PD-L1 inhibitor with a more favorable profile. | Drug: INCB086550 | Non Small Cell Lung Cancer, Urothelial Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma, Melanoma | 16 | 2021-09-02 | 2024-03-26actual | — | 2025-03-13 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid TumorsNCT05126433results2025-02-28Investigator-Assessed Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 | Phase 2 | Terminatedsponsor's stated reason: Termination of this study was a business decision made during portfolio review. | Drug: Lurbinectedin | Advanced Solid Tumor, Metastatic Solid Tumor, Urothelial Cancer, Poorly Differentiated Neuroendocrine Carcinomas, Homologous Recombination Deficient-Positive Malignancies Agnostic | 47 | 2022-03-03 | 2023-12-20actual | — | 2025-02-28 |
| URGN | UroGen Pharma Ltd. | $2.4B | Named Patient Program for Mitomycin for Pyelocalyceal SolutionNCT05494411expanded access | — | Available | Drug: Mitomycin for pyelocalyceal solution | Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Ureter, Urothelial Carcinoma Ureter Recurrent, Urothelial Carcinoma, Urothelial Carcinoma Recurrent | — | — | — | — | 2025-02-28 |
| URGN | UroGen Pharma Ltd. | $2.4B | uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With JelmytoNCT05874921observationalRate of CR or no evidence of disease (NED) at first evaluation post-treatment | — | Recruiting | Drug: Jelmyto (mitomycin) for pyelocalyceal solution | Urothelial Carcinoma, Urothelial Carcinoma Recurrent, Urothelial Carcinoma Ureter, Urothelial Carcinoma Ureter Recurrent, Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma of the Renal Pelvis and Ureter, Carcinoma, Transitional Cell, Transitional Cell Carcinoma of Renal Pelvis | 400 | 2023-11-17 | Apr 2026 | — | 2025-02-28 |
| IBRX | ImmunityBio, Inc. | $8.2B | QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyNCT03197571Incidence of treatment-emergent adverse events (AEs) and serious AEs (SAEs), graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. | Phase 1/2 | Withdrawnsponsor's stated reason: Trial not initiated | Biological: avelumab, bevacizumab, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK · Drug: capecitabine, cisplatin, cyclophosphamide, 5Fluorouracil (5-FU), fulvestrant, leucovorin, nab-paclitaxel, Lovaza · Radiation: Stereotactic Body Radiation Therapy | Urothelial Carcinoma | 0 | Dec 2017 | Jan 2019 | — | 2025-02-21 |
| 4568.T | Daiichi Sankyo | $31.7B | Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial CancerNCT03523572results2025-01-27Number of Participants With Dose-Limiting Toxicities at 3.2 mg/kg and 5.4 mg/kg Dose Level in Participants With HER2-expressing Advanced Breast Cancer in Dose Escalation | Phase 1 | Completed | Drug: Trastuzumab deruxtecan, Nivolumab | Breast Cancer, Urothelial Carcinoma | 86 | 2018-08-02 | 2021-07-22actual | — | 2025-01-27 |
| PFE | Pfizer | $155.3B | A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In CombinationNCT06448364PART 1: Number of participants with Dose-limiting toxicities (DLT) | Phase 1 | Terminatedsponsor's stated reason: Strategic business decision | Biological: PF-07329640, sasanlimab, bevacizumab | Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Urothelial Cancer, Melanoma | 4 | 2024-05-09 | 2024-08-15actual | — | 2024-11-06 |
| 4503.T | Astellas Pharma Inc | $26.0B | A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial CarcinomaNCT03070990Safety assessed by incidence of adverse events | Phase 1 | Completed | Drug: Enfortumab vedotin | Metastatic Urothelial Cancer | 19 | 2017-04-24 | 2019-02-25actual | — | 2024-10-18 |
| URGN | UroGen Pharma Ltd. | $2.4B | Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)NCT05136898results2024-09-19Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation, and TEAEs of Special Interest. | Phase 3 | Completed | Drug: UGN-102 | Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder | 8 | 2021-11-30 | 2023-02-02actual | — | 2024-09-19 |
| 4503.T | Astellas Pharma Inc | $26.0B | A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder CancerNCT03219333results2021-12-17Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) | Phase 2 | Completed | Drug: Enfortumab vedotin | Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms, Urothelial Cancer, Ureteral Neoplasms, Urethral Neoplasms | 219 | 2017-10-08 | 2020-10-27actual | — | 2024-08-27 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract CancerNCT02443324results2024-07-31Phase 1a: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) | Phase 1 | Completed | Drug: Ramucirumab, Pembrolizumab | Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell, Biliary Tract Cancer | 175 | 2015-07-29 | 2018-08-31actual | — | 2024-07-31 |
| PFE | Pfizer | $155.3B | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid TumorsNCT04628780results2024-07-29Number of Participants With Dose Limiting Toxicities (DLTs) | Phase 1 | Terminatedsponsor's stated reason: Pfizer has made an internal business decision to not continue further development of PF-07209960. This decision was not based on safety or regulatory considerations | Biological: PF-07209960 | Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Urothelial Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma | 37 | 2020-12-16 | 2023-05-03actual | — | 2024-07-29 |
| XNCR | Xencor, Inc. | $1.9B | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)NCT03752398Treatment-related adverse events as assessed by CTCAE v4.03 | Phase 1 | Completed | Biological: XmAb®23104, Yervoy® (ipilimumab) | Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced Solid Tumors, Undifferentiated Pleomorphic Sarcoma | 198 | 2019-05-01 | 2024-02-15actual | — | 2024-07-05 |
| URGN | UroGen Pharma Ltd. | $2.4B | A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerNCT04688931results2024-06-06Disease-free Survival (DFS) | Phase 3 | Terminatedsponsor's stated reason: Alternate approach pursued | Drug: UGN-102 · Procedure: TURBT | Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder | 282 | 2021-02-19 | 2023-03-17actual | — | 2024-06-06 |
| 4151.T | Kyowa Kirin, Inc. | $8.4B | KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder CancerNCT03915405Number of participants with treatment-related adverse events as assessed by CTCAE v.5.0 | Phase 1 | Terminatedsponsor's stated reason: Termination was based on the business decision | Drug: KHK2455, Avelumab | Urothelial Carcinoma | 16 | 2019-09-26 | 2022-11-15actual | — | 2024-04-25 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder CancerNCT05699135observationalOverall survival | — | Terminatedsponsor's stated reason: The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns. | Drug: Avelumab first-line maintenance | Urinary Bladder Neoplasms, Bladder Cancer, Bladder Tumors, Urothelial Carcinoma | 150 | 2023-03-09 | 2023-06-30actual | — | 2024-04-24 |
| PFE | Pfizer | $155.3B | A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)NCT03472560results2024-04-09Percentage of Participants With Confirmed Objective Response- Objective Response Rate (ORR) | Phase 2 | Terminatedsponsor's stated reason: The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the Investigational treatments have been moved to a continuation study (NCT05059522) | Drug: Avelumab (MSB0010718C), Axitinib (AG-013736) | Non-Small Cell Lung Cancer, Urothelial Cancer | 61 | 2018-05-02 | 2023-02-09actual | — | 2024-04-09 |
| CLDX | Celldex Therapeutics | $3.3B | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced MalignanciesNCT03329950Safety and Tolerability of CDX-1140 as assessed by CTCAE v5.0 | Phase 1 | Completed | Drug: CDX-1140, CDX-301, pembrolizumab, Chemotherapy | Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Cholangiocarcinoma, Bladder Urothelial Carcinoma, Pancreatic Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Head and Neck Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Other Solid Tumors, Diffuse Large B-cell Lymphoma (DLBCL), Mantle Cell Lymphoma, Indolent B-cell Lymphomas, Non-Hodgkin Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Waldenstrom's Disease, Marginal Zone Lymphoma, Mucosa Associated Lymphoid Tissue, Small Lymphocytic Leukemia | 132 | 2017-12-01 | 2022-09-13actual | — | 2024-03-28 |
| PFE | Pfizer | $155.3B | A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)NCT02603432results2020-12-17Overall Survival (OS) | Phase 3 | Completed | Biological: Avelumab, Following the planned interim analysis for this study: Avelumab · Other: Best Supportive Care | Urothelial Cancer | 700 | 2016-04-25 | 2019-10-21actual | — | 2024-03-27 |
| NXTC | NextCure, Inc. | $30M | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid TumorsNCT03665285results2024-03-08Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0 | Phase 1/2 | Completed | Drug: NC318 | Advanced or Metastatic Solid Tumors, Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Endometrial Cancer, Melanoma, CRC, Urothelial Carcinoma, Cholangiocarcinoma | 109 | 2018-10-01 | 2023-04-11actual | — | 2024-03-08 |
| AZN | AstraZeneca | — | Prevalence of PD-L1 Expression in Patients With Advanced Urothelial CarcinomaNCT03788746observationalCategorization of PD-L1 results (dichotomous, high vs. low) based on pre-treatment tissue samples. | — | Completed | — | Urothelial Carcinoma | 181 | 2019-01-17 | 2022-01-12actual | — | 2024-02-22 |
| FATE | Fate Therapeutics | $307M | Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular ImmunotherapyNCT04106167observationalOverall Survival (OS) post-Infusion | — | Terminatedsponsor's stated reason: This study was terminated by the Sponsor. | Genetic: Allogeneic natural killer (NK) cell | Advanced Solid Tumor, Lymphoma, Gastric Cancer, Colorectal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, EGFR Positive Solid Tumor, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Small-cell Lung Cancer, Renal Cell Carcinoma, Pancreas Cancer, Melanoma, NSCLC, Urothelial Carcinoma, Cervical Cancer, Microsatellite Instability, Merkel Cell Carcinoma | 20 | 2019-06-11 | 2023-08-11actual | — | 2023-09-21 |
| PFE | Pfizer | $155.3B | Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced MalignanciesNCT03317496results2022-06-23Phase 1b Lead-in: Number of Participants With Dose-Limiting Toxicities (DLT) | Phase 1/2 | Terminatedsponsor's stated reason: The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the investigational treatments have been moved to a continuation study (NCT05059522). | Drug: Avelumab 800 mg in combination with pemetrexed / carboplatin, Avelumab 800 mg in combination with gemcitabine / cisplatin., Avelumab 1200 mg in combination with pemetrexed/carboplatin, Avelumab 1200 mg in combination with gemcitabine/cisplatin | Non-small Cell Lung Cancer, Urothelial Cancer | 67 | 2017-12-21 | 2021-06-07actual | — | 2023-08-29 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial CancerNCT02426125results2019-03-08Progression Free Survival (PFS) | Phase 3 | Completed | Drug: Ramucirumab, Docetaxel, Placebo | Urothelial Carcinoma | 530 | 2015-07-13 | 2017-04-21actual | — | 2023-08-21 |
| INCY | Incyte Corporation | $24.7B | A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)NCT03679767results2022-05-10Overall Response Rate (ORR) | Phase 2 | Completed | Drug: Retifanlimab | Metastatic Non-small Cell Lung Cancer, Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer, Unresectable Melanoma, Metastatic Melanoma, Locally Advanced Renal Cell Carcinoma, Metastatic Clear-Cell Renal Cell Carcinoma | 121 | 2019-01-09 | 2021-04-15actual | — | 2023-07-21 |
| TPST | Tempest Therapeutics | $16M | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced CancersNCT03829436Incidence of dose limiting toxicities (DLTs) of TPST-1120 as a single agent and in combination with nivolumab. | Phase 1 | Completed | Drug: Part 1 TPST-1120, Part 2 TPST-1120 + nivolumab, Part 3 TPST-1120, Part 4 TPST-1120 + nivolumab | Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma of Head and Neck, Triple-Negative Breast Cancer, Urothelial Carcinoma, Cholangiocarcinoma, GastroEsophageal Cancer, Pancreatic Cancer, Sarcoma | 38 | 2019-03-20 | 2022-09-07actual | — | 2023-07-03 |
| CLDX | Celldex Therapeutics | $3.3B | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced MalignanciesNCT04440943Safety and Tolerability of CDX-527 as assessed by CTCAE v5.0 | Phase 1 | Completed | Drug: CDX-527 | Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cholangiocarcinoma, Bladder Urothelial Carcinoma, MSI-H Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Head and Neck Cancer, Other Solid Tumors | 27 | 2020-08-04 | 2023-04-06actual | — | 2023-06-18 |
| FATE | Fate Therapeutics | $307M | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsNCT03841110The incidence of participants with Dose Limiting Toxicities (DLTs) within each dose level cohort. | Phase 1 | Completed | Drug: FT500, Nivolumab, Pembrolizumab, Atezolizumab, Cyclophosphamide, Fludarabine, IL-2 | Advanced Solid Tumors, Lymphoma, Gastric Cancer, Colorectal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, EGFR Positive Solid Tumor, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Small Cell Lung Cancer, Renal Cell Carcinoma, Pancreas Cancer, Melanoma, NSCLC, Urothelial Carcinoma, Cervical Cancer, Microsatellite Instability, Merkel Cell Carcinoma | 37 | 2019-02-15 | 2022-11-15actual | — | 2023-05-01 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder CancerNCT05496192Proportion of Participants That Prefer Nivolumab SC at the First Assessment of Patient Preference Using Patient Experience and Preference Questionnaire (PEPQ) (Question 1) | Phase 2 | Withdrawnsponsor's stated reason: Replaced it with another clinical trial | Drug: Nivolumab/rHuPH20, Nivolumab | Melanoma, Urothelial Carcinoma | 0 | 2023-05-31 | 2024-06-24 | — | 2023-04-14 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Urothelial Carcinoma is matched — 19 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Urothelial Carcinoma
- Urothelial Cancer
- Urothelial Carcinoma Bladder
- Carcinoma, Transitional Cell
- UC (Urothelial Cancer)
- Metastatic Urothelial Cancer
- Metastatic Urothelial Carcinoma
- Transitional Cell Carcinoma
- Urothelial Carcinoma Recurrent
- Bladder (Urothelial, Transitional Cell) Cancer
- Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
- Bladder Urothelial Carcinoma
- Urothelial Cancer of Renal Pelvis
- Transitional Cell Cancer of the Renal Pelvis and Ureter
- Transitional Cell Carcinoma of Renal Pelvis
- Urothelial Carcinoma (UC)
- Urothelial Carcinoma Ureter
- Urothelial Carcinoma Ureter Recurrent
- Urothelial Carcinoma of the Renal Pelvis and Ureter
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Urothelial Carcinoma” (a text search, wider than this page)